Switch theme
Sign up to access all valuation multiples
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
1944
36.8K+
LTM Revenue $16.4B
LTM EBITDA $4.7B
$30.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Teva Pharmaceuticals has a last 12-month revenue of $16.4B and a last 12-month EBITDA of $4.7B.
In the most recent fiscal year, Teva Pharmaceuticals achieved revenue of $4.5B and an EBITDA of $211M.
Teva Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Teva Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.5B | XXX | XXX | XXX |
| Gross Profit | $1.9B | $2.1B | XXX | XXX | XXX |
| Gross Margin | 44% | 46% | XXX | XXX | XXX |
| EBITDA | $422M | $211M | XXX | XXX | XXX |
| EBITDA Margin | 10% | 5% | XXX | XXX | XXX |
| Net Profit | -$638M | -$152M | XXX | XXX | XXX |
| Net Margin | -15% | -3% | XXX | XXX | XXX |
| Net Debt | $5.0B | $4.5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Teva Pharmaceuticals's stock price is ILS 51 (or $14).
Teva Pharmaceuticals has current market cap of ILS 58.0B (or $15.7B), and EV of ILS 113B (or $30.7B).
See Teva Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30.7B | $15.7B | XXX | XXX | XXX | XXX | $2.46 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Teva Pharmaceuticals has market cap of $15.7B and EV of $30.7B.
Teva Pharmaceuticals's trades at 1.9x LTM EV/Revenue multiple, and 6.5x LTM EBITDA.
Analysts estimate Teva Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Teva Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $30.7B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | XXX | XXX |
| EV/EBITDA | 145.5x | XXX | XXX | XXX |
| P/E | -35.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 150.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTeva Pharmaceuticals's NTM/LTM revenue growth is 4%
Teva Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $35K for the same period.
Over next 12 months, Teva Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Teva Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Teva Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -50% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 9% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $35K | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 15% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 28% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Teva Pharmaceuticals acquired XXX companies to date.
Last acquisition by Teva Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Teva Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Teva Pharmaceuticals founded? | Teva Pharmaceuticals was founded in 1944. |
| Where is Teva Pharmaceuticals headquartered? | Teva Pharmaceuticals is headquartered in Israel. |
| How many employees does Teva Pharmaceuticals have? | As of today, Teva Pharmaceuticals has 36.8K+ employees. |
| Who is the CEO of Teva Pharmaceuticals? | Teva Pharmaceuticals's CEO is Mr. Richard D. Francis. |
| Is Teva Pharmaceuticals publicy listed? | Yes, Teva Pharmaceuticals is a public company listed on TAE. |
| What is the stock symbol of Teva Pharmaceuticals? | Teva Pharmaceuticals trades under TEVA ticker. |
| When did Teva Pharmaceuticals go public? | Teva Pharmaceuticals went public in 1961. |
| Who are competitors of Teva Pharmaceuticals? | Similar companies to Teva Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Teva Pharmaceuticals? | Teva Pharmaceuticals's current market cap is $15.7B |
| What is the current revenue of Teva Pharmaceuticals? | Teva Pharmaceuticals's last 12-month revenue is $16.4B. |
| What is the current EBITDA of Teva Pharmaceuticals? | Teva Pharmaceuticals's last 12-month EBITDA is $4.7B. |
| What is the current EV/Revenue multiple of Teva Pharmaceuticals? | Current revenue multiple of Teva Pharmaceuticals is 1.9x. |
| What is the current EV/EBITDA multiple of Teva Pharmaceuticals? | Current EBITDA multiple of Teva Pharmaceuticals is 6.5x. |
| What is the current revenue growth of Teva Pharmaceuticals? | Teva Pharmaceuticals revenue growth between 2023 and 2024 was 4%. |
| Is Teva Pharmaceuticals profitable? | Yes, Teva Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
